LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

LLY

1,015.5

+2.79%↑

JNJ

230.41

+2.69%↑

ABBV

208.54

+0.36%↑

UNH

400.53

+1.04%↑

AZN

187.75

+1.77%↑

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

3.27 0.93

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.17

Максимум

3.3

Ключови измерители
By Trading Economics
Приходи	1.3M -3M
Продажби	100K 100K
Марж на печалбата	-2,954
Служители	21

Дивиденти
By Dow Jones
Следващи печалби	14.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-16M 23M
Предишно отваряне	2.34
Предишно затваряне	3.27

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.05.2026 г., 22:50 ч. UTC

Печалби

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12.05.2026 г., 22:49 ч. UTC

Печалби

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12.05.2026 г., 22:32 ч. UTC

Печалби

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12.05.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12.05.2026 г., 22:57 ч. UTC

Пазарно говорене

Печалби

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12.05.2026 г., 22:26 ч. UTC

Печалби

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12.05.2026 г., 22:25 ч. UTC

Печалби

Aristocrat Leisure Interim Dividend A$0.50/Security

12.05.2026 г., 22:24 ч. UTC

Печалби

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12.05.2026 г., 22:23 ч. UTC

Печалби

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12.05.2026 г., 22:19 ч. UTC

Печалби

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA: Business Lending Continued to Grow Above System>CBA.AU

12.05.2026 г., 22:14 ч. UTC

Печалби

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12.05.2026 г., 22:13 ч. UTC

Печалби

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12.05.2026 г., 22:12 ч. UTC

Печалби

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12.05.2026 г., 22:11 ч. UTC

Печалби

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12.05.2026 г., 22:11 ч. UTC

Печалби

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12.05.2026 г., 22:10 ч. UTC

Печалби

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12.05.2026 г., 22:09 ч. UTC

Печалби

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12.05.2026 г., 22:08 ч. UTC

Печалби

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12.05.2026 г., 22:07 ч. UTC

Печалби

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12.05.2026 г., 22:06 ч. UTC

Печалби

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12.05.2026 г., 22:05 ч. UTC

Печалби

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12.05.2026 г., 22:04 ч. UTC

Печалби

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Печалба преди облагане с данъци

Продажби

Оперативна печалба

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.